STOCK TITAN

Alaunos Therapeutics (TCRT) director granted 8,463 shares for board fees

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Robert W. Postma, a director of Alaunos Therapeutics, Inc., reported the acquisition of 8,463 shares of common stock on 23 July 2026 at $1.92 per share, described as shares issued in lieu of board fees. Following this grant, he holds 58,609 shares directly and additional indirect holdings of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp.

Positive

  • None.

Negative

  • None.
Insider Postma Robert W
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 8,463 $1.92 $16K
holding Common Stock -- -- --
holding Common Stock F2 -- -- --
Holdings After Transaction: Common Stock — 58,609 shares (Direct); Common Stock — 24 shares (Indirect, By spouse's IRA); Common Stock — 62,416 shares (Indirect, By WaterMill Asset Management Corp.(2))
Footnotes (2)
  1. F1. Represents shares of common stock issued in lieu of board fees.
  2. F2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill
Shares acquired 8463.0000 shares Common stock issued in lieu of board fees on 23 July 2026
Grant value per share $1.9200 per share Stated value for the 8,463-share issuance
Direct holdings after grant 58609.0000 shares Common stock directly held by Robert W. Postma after the transaction
Indirect holdings via spouse's IRA 24.0000 shares Common stock held indirectly by spouse's IRA
Indirect holdings via WaterMill 62416.0000 shares Common stock held indirectly through WaterMill Asset Management Corp.
in lieu of board fees financial
"Represents shares of common stock issued in lieu of board fees."
indirect ownership financial
"Shares reported as indirect ownership, including by spouse's IRA and by WaterMill."
IRA financial
"Nature of ownership noted as "By spouse's IRA" for 24 shares."
An individual retirement account (IRA) is a savings account designed to help people put aside money for their retirement, often with tax advantages that encourage long-term savings. It matters to investors because it can grow over time, providing financial security later in life, and offers benefits that can reduce current taxes or allow investments to compound more effectively.
WaterMill Asset Management Corp. financial
"The shares are directly held by WaterMill Asset Management Corp. ("WaterMill")."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Robert W. Postma report for Alaunos Therapeutics (TCRT)?

Director Robert W. Postma reported receiving 8,463 shares of Alaunos Therapeutics common stock on 23 July 2026. The shares were issued in lieu of board fees at a stated value of $1.92 per share and recorded as a grant or award acquisition.

How many Alaunos Therapeutics (TCRT) shares did Postma acquire and at what value?

Postma acquired 8,463 shares of Alaunos Therapeutics common stock valued at $1.92 per share. According to the filing, these shares were issued in lieu of board fees rather than a market purchase, and are classified as a grant, award, or other acquisition of common stock.

What are Robert W. Postma’s direct share holdings in Alaunos Therapeutics (TCRT) after this transaction?

After the reported grant, Postma directly holds 58,609 shares of Alaunos Therapeutics common stock. This total reflects his position following the issuance of 8,463 shares in lieu of board fees on 23 July 2026, as disclosed in the Form 4 filing.

Was Robert W. Postma’s Alaunos Therapeutics (TCRT) share grant described as compensation?

Yes. The Form 4 footnote states the 8,463 shares of Alaunos common stock were “issued in lieu of board fees.” This indicates the shares represent compensation for board service rather than a discretionary open-market stock purchase by the director.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Postma Robert W

(Last)(First)(Middle)
501 E LAS OLAS BLVD
SUITE 300

(Street)
FORT LAUDERDALE FLORIDA 33301

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026A8,463(1)A$1.9258,609D
Common Stock24IBy spouse's IRA
Common Stock62,416(2)IBy WaterMill Asset Management Corp.(2)(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock issued in lieu of board fees.
2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill
Postma Robert W07/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)